Kelsey Kubelick , Nicholas Boulis, MD
Summary
Stem cell therapy is a promising option to treat amyotrophic lateral sclerosis (ALS), the most common adult-onset neurodegenerative disease of motor neurons in the spinal cord. However, several factors are inhibiting clinical translation: 1) intra-operative real-time guidance of the stem cell injection; and 2) postoperative stem cell tracking. Thus, we have synthesized photomagnetic nanocubes (PMNCs; Fig. 1A) to safely label stem cells for intraoperative, ultrasound/photoacoustic (US/PA) image-guided delivery of stem cells and postoperative US/PA/MRI tracking of stem cells in vivo.
Mesenchymal stem cells (MSCs) were labeled with PMNCs (PMNC-MSCs) by incubation in cell culture for 24 h (Fig. 1B). Per the clinical procedure, a lumbar laminectomy was performed in nude rats to remove the bone and expose the underlying spinal cord. PMNC-MSCs (5µL) were injected directly into the spinal cord (Fig. 1C). The muscle and skin were sutured back over the spinal cord, but the bone was not replaced. US/PA and MR datasets were acquired in vivo.
In intraoperative studies, US depicted spinal cord anatomy (Fig. 1D), while PA imaging (750 nm) visualized needle placement (Fig. 1E) in real-time to guide the injection (Fig. 1F), which could improve procedure safety and efficacy. The average PA signal increased with injection volume (Fig. 1G), indicating potential for quantitative feedback. At 10 days post-injection, US/PA and MR images still detected PMNC-MSCs (red arrows), and good agreement was observed between modalities (Fig. 1H–K).
Our results demonstrate the ability of US/PA/MRI to assist clinicians and researchers throughout treatment by providing a customizable tool for intraoperative guidance and postoperative, longitudinal monitoring of stem cells in the spinal cord.
Further Reading
- Donnelly EM, Kubelick KP, Dumani DS, Emelianov SY. Photoacoustic Image-Guided Delivery of Plasmonic-Nanoparticle-Labeled Mesenchymal Stem Cells to the Spinal Cord. Nano letters. 2018 Aug 30;18(10):6625-32.